Biotech Values

[DewDiligence]

Good calls.

>What is amazing to me is how long it takes the medical establishment to figure out things like this. It was pretty obvious 5 years ago - and worthy of investigation 10 years ago.<

For AZN, the unfortunate aspect of the delay is that Crestor has already used up five years of its US patent life being a much less consequential drug than it probably could have been.